DK0923934T3 - Modified release-matrixformulering af cefaclor og cephalexin - Google Patents

Modified release-matrixformulering af cefaclor og cephalexin

Info

Publication number
DK0923934T3
DK0923934T3 DK98302445T DK98302445T DK0923934T3 DK 0923934 T3 DK0923934 T3 DK 0923934T3 DK 98302445 T DK98302445 T DK 98302445T DK 98302445 T DK98302445 T DK 98302445T DK 0923934 T3 DK0923934 T3 DK 0923934T3
Authority
DK
Denmark
Prior art keywords
hydrophilic polymers
cephalexin
cefaclor
active ingredient
weight
Prior art date
Application number
DK98302445T
Other languages
English (en)
Inventor
Jagdish Arora
Girish Jain
Himadri Sen
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of DK0923934T3 publication Critical patent/DK0923934T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DK98302445T 1997-12-17 1998-03-30 Modified release-matrixformulering af cefaclor og cephalexin DK0923934T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/992,151 US5948440A (en) 1997-12-17 1997-12-17 Modified release matrix formulation of cefaclor and cephalexin

Publications (1)

Publication Number Publication Date
DK0923934T3 true DK0923934T3 (da) 2003-11-24

Family

ID=25537971

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98302445T DK0923934T3 (da) 1997-12-17 1998-03-30 Modified release-matrixformulering af cefaclor og cephalexin

Country Status (9)

Country Link
US (1) US5948440A (da)
EP (1) EP0923934B1 (da)
AT (1) ATE246505T1 (da)
AU (1) AU741361B2 (da)
DE (1) DE69816951T2 (da)
DK (1) DK0923934T3 (da)
ES (1) ES2203885T3 (da)
NZ (1) NZ329679A (da)
PT (1) PT923934E (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IT1318495B1 (it) * 2000-05-04 2003-08-25 Lisapharma Spa Formulazioni farmaceutiche, a rilascio modificato, con elevatabiodisponibilita', contenenti principi attivi ad attivita'
JP5049450B2 (ja) 2000-09-29 2012-10-17 アボツト・ヘルスケア・プロダクツ・ベー・ブイ イオン強度に依存しない徐放性製薬組成物
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
PT1461017E (pt) * 2001-11-19 2006-07-31 Lupin Ltd Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico
US20040033262A1 (en) * 2002-08-19 2004-02-19 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
AU2003255874A1 (en) * 2002-08-16 2004-03-03 Orchid Health Care, A Division Of Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition of a cephalosporin antibiotic
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) * 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
BR0318535A (pt) * 2003-09-30 2006-09-12 Lupin Ltd composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
WO2005039499A2 (en) * 2003-10-24 2005-05-06 Adhesives Research, Inc. Rapidly disintegrating film
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
RU2378272C2 (ru) * 2004-07-30 2010-01-10 Торрент Фармасьютикалз Лимитед Небиволол и его фармацевтически приемлемые соли, способ их получения и фармацевтические композиции небиволола
CA2581373C (en) * 2004-09-30 2013-07-23 The Hershey Company Sealed, edible film strip packets and methods of making and using them
ES2557165T3 (es) * 2006-04-12 2016-01-22 Nippon Soda Co., Ltd. Método para producir una tableta de liberación sostenida
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
PL2395840T3 (pl) 2009-02-13 2020-09-07 Romark Laboratories, L.C. Preparaty farmaceutyczne nitazoksanidu o kontrolowanym uwalnianiu
FR2962550B1 (fr) * 2010-07-06 2013-06-14 Ethypharm Sa Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode
CN101912373B (zh) * 2010-08-24 2012-01-04 北京京丰制药有限公司 稳定的头孢克洛分散片及其制备方法
CN112137984B (zh) * 2020-10-30 2023-02-03 四川制药制剂有限公司 头孢克洛胶囊及其制备工艺
CN113750066B (zh) * 2021-10-12 2022-12-02 上海金城素智药业有限公司 一种具有临床优势的头孢克洛制剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
JPS6024765B2 (ja) * 1981-11-27 1985-06-14 辰巳化学株式会社 セフアレキシンの持続性製剤の製造方法
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
DE3607946A1 (de) * 1986-03-11 1987-09-17 Basf Ag Verfahren zur einengung der molekulargewichtsverteilung von polytetrahydrofuran und von copolymerisaten aus tetrahydrofuran und alkylenoxiden
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
AU609234B2 (en) * 1987-12-21 1991-04-26 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
ATE216887T1 (de) * 1996-02-29 2002-05-15 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung

Also Published As

Publication number Publication date
NZ329679A (en) 1999-10-28
DE69816951D1 (de) 2003-09-11
AU5290698A (en) 1999-07-08
ES2203885T3 (es) 2004-04-16
PT923934E (pt) 2003-12-31
EP0923934A1 (en) 1999-06-23
ATE246505T1 (de) 2003-08-15
AU741361B2 (en) 2001-11-29
US5948440A (en) 1999-09-07
DE69816951T2 (de) 2004-06-17
EP0923934B1 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
DK0923934T3 (da) Modified release-matrixformulering af cefaclor og cephalexin
US6177102B1 (en) Once daily analgesic tablet
CA2592173C (en) Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
YU71894A (sh) Novi farmaceutski preparat sa difuziono-osmotskom kontrolom oslobađanja leka i postupak za dobivanje istog
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
NO975872D0 (no) Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
CA2290531A1 (en) Pharmaceutical formulation of omeprazole
NZ322053A (en) Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers
CZ225596A3 (en) Film-coated tablets of paracetamol and domperidon
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
JP4660192B2 (ja) スフェロイド、その製造方法および医薬組成物
MXPA01008893A (es) Composiciones de betahistina de liberacion controlada.
JPS6117510A (ja) 口腔粘膜適用徐放性ニフエジピン製剤
ATE361080T1 (de) Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
MY114610A (en) Controlled drug delivery system for diltiazem.